Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065410 | 1.00 | SCN10A (0.44) | SCN10ASCN2ANAMPTTDP1GPR119 | |
| SCHEMBL2065970 | 0.88 | SCN10A (0.48) | SCN10ASCN2A | |
| SCHEMBL2065971 | 0.88 | SCN10A (0.48) | SCN10ASCN2A | |
| SCHEMBL2065508 | 0.86 | SCN2A (0.44) | SCN10ASCN2ANAMPTTDP1GPR119 | |
| SCHEMBL2065506 | 0.86 | SCN2A (0.44) | SCN10ASCN2ANAMPTTDP1GPR119 | |
| SCHEMBL2065334 | 0.85 | SCN10A (0.44) | SCN10ASCN2ANAMPT | |
| SCHEMBL2065335 | 0.85 | SCN10A (0.44) | SCN10ASCN2ANAMPT | |
| SCHEMBL1134559 | 0.81 | SCN10A (0.49) | SCN10ASCN2A | |
| SCHEMBL23109075 | 0.79 | HCRTR1 (0.49) | GPR119HCRTR1HCRTR2USP30 | |
| SCHEMBL2065048 | 0.77 | LMNA (0.48) | NAMPTTDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2700639-A1 | Selective ligands for the neuronal nicotinic receptors and uses thereof | Abbvie Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| US-8148408-B2 | Selective substituted pyridine ligands for neuronal nicotinic receptors | ABBOTT LABORATORIES (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090281118-A1 | Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof | ABBOTT LABORATORIES (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281118-A1 | Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof | CHRNA4, CHRNB4, CHRNA2 | SCN10A 139/4885SCN2A 113/4885NAMPT 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.